| Literature DB >> 32979378 |
Riccardo Campi1, Riccardo Tellini2, Antonio Andrea Grosso2, Daniele Amparore3, Andrea Mari4, Lorenzo Viola2, Andrea Cocci2, Paolo Polverino2, Enrico Checcucci3, Paolo Alessio3, Cristian Fiori3, Andrea Minervini4, Marco Carini4, Francesco Porpiglia3, Sergio Serni4.
Abstract
OBJECTIVES: To explore the perspective of urological patients on the possibility to defer elective surgery due to the fear of contracting COVID-19.Entities:
Year: 2020 PMID: 32979378 PMCID: PMC7513799 DOI: 10.1016/j.urology.2020.09.015
Source DB: PubMed Journal: Urology ISSN: 0090-4295 Impact factor: 2.649
Baseline Characteristics of Patients Included in the Study and Main Study Outcomes
| Patient Characteristics | ||
|---|---|---|
| Center (n,%) | Florence | 224 (67.5) |
| Turin | 108 (32.5) | |
| Age (years) (n,%) | ≤60 | 82 (24.7) |
| 61-80 | 209 (63.0) | |
| >80 | 41 (12.3) | |
| Level of education (n,%) | Primary/secondary school | 143 (43.1) |
| High school/University | 189 (56.9) | |
| ASA score (n,%) | 1-2 | 256 (77.1) |
| 3-4 | 76 (22.9) | |
| Disease characteristics | ||
| Nature of the disease (n,%) | Benign | 171 (51.5) |
| Malignant | 161 (48.5) | |
| Type of benign disease (n,%) | Stone / Upper tract functional disease | 43 (26.7) |
| Andrological disease | 25 (15.5) | |
| BPH / female functional disease | 93 (57.8) | |
| Type of cancer (n,%) | Prostate Cancer | 67 (38.7) |
| Urothelial Cancer | 77(44.5) | |
| Renal Cell Carcinoma | 29 (16.8) | |
| Priority of uro-oncologic surgery | High Priority | 51 (19.5) |
| Low Priority | 210 (80.5) | |
| Main outcomes | ||
| Q1: In light of the COVID-19 pandemic, would you defer your planned surgical intervention? | Yes | 159 (47.9) |
| No | 173 (52.1) | |
| Q2: If yes, when would you be willing to undergo surgery? | <3 months | 24 (15.1) |
| >6 months | 135 (84.9) | |
| Q3:Which of the following do you consider potentially more harmful for your health? | Risk of contracting COVID-19 during hospitalization | 182 (54.8) |
| Risk of delaying surgical treatment | 150 (45.2) | |
BPH, benign prostatic hyperplasia.
Figure 1Patients’ perspectives on refusal of elective urological surgery and their drivers, stratified by the nature of underlying urological condition (malignant disease [group A] vs benign disease [group B]). The factors influencing the answers to questions Q1-Q3 are shown in the lower portion of the figure and are highlighted in light grey (for patient-related variables) and dark grey (for disease-related variables). ASA, American Society of Anesthesiologists. (Color version available online.)
Influence of Patient- and Disease-related Characteristics on Patients’ Perspective Regarding the Refusal of Elective Surgery in Our Study Population
| Patients With Urological Cancers | Age (Y) | p | Education | p | ASA Score | p | Type of Cancer | P | Priority of Uro-oncological Surgery | p | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <60 | 61-80 | > 80 | Primary / Secondary School | High-School / University | ASA 1-2 | ASA 3-4 | Prostate | Urothelial | Renal | Low | High | |||||||
| Q1: In light of the COVID-19 pandemic, would you defer the planned surgical intervention? | 7 (21.2) | 34 (31.2) | 16 (55.2) | 30 (37.5) | 27 (29.7) | 0.3 | 36 (29.0) | 21 (44.7) | 21 (31.8) | 30 (39.5) | 6 (20.7) | 0.2 | 42 (34.4) | 15 (30.6) | 0.6 | |||
| Q2: If yes, when would you be willing to undergo surgery? | <3 months | 1 (14.3) | 8 (23.5) | 1 (6.3) | 0.3 | 6 (20.0) | 4 (14.8) | 0.6 | 3 | 7 (33.3) | 3 (14.3) | 7 (23.3) | 0 (0) | 0.4 | 5 (11.9) | 5 (33.3) | ||
| >6 months | 6 (85.7) | 26 (76.5) | 15 (93.8) | 24 (80.0) | 23 (85.2) | 33 (91.7) | 14 (66.7) | 18 (85.7) | 23 (76.7) | 6 (100) | 37 (88.1) | 10 (66.7) | ||||||
| Q3: Which of the following do you consider potentially more harmful for your health: | Risk of contracting COVID-19 during hospitalization | 9 (27.3) | 35 (32.1) | 20 (69.0) | 36 (45.0) | 28 (30.8) | 42 (33.9) | 22 (46.8) | 0.1 | 19 (28.8) | 38 (50.0) | 7 (24.1) | 48 (39.3) | 16 (32.7) | 0.4 | |||
| Risk of delaying surgery | 24 (72.7) | 74 (67.9) | 9 (31.0) | 44 (55.0) | 63 (69.2) | 82 (66.1) | 25 (53.2) | 47 (71.2) | 38 (50.0) | 22 (75.9) | 74 (60.7) | 33 (67.3) | ||||||
ASA, American Society of Anesthesiologists.
Data are presented separately for the cohort of patients scheduled for uro-oncological surgery and for those scheduled for surgery for benign urological conditions.
Bold values are those that are “statistically significant” (p<0.05).